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ABSTRACT
The in-vivo activities of cefepime, imipenem and meropenem against the porin-deﬁcient strain Klebsiella
pneumoniae C2 and its derivative K. pneumoniae C2(pMG252) coding for the AmpC-type b-lactamase
FOX-5 were determined. Bactericidal activities were determined with the kill-curve method. A
pneumonia model in guinea-pigs was developed, and Cmax, t½ and DT ⁄MIC were calculated for the
three agents tested. Animals were treated for 72 h with sterile saline (control group) or with cefepime,
imipenem or meropenem (240 mg ⁄kg ⁄day, intramuscularly, three times daily). Bacterial counts in lungs
(log10 CFU ⁄ g tissue) were determined by serial dilution. MICs (mg ⁄L) of cefepime, imipenem and
meropenem against K. pneumoniae C2 ⁄K. pneumoniae C2(pMG252), determined by macrodilution, were:
0.5 ⁄ 4, 0.5 ⁄ 0.5 and 0.25 ⁄ 0.5, respectively. Bacterial counts in the lungs of animals infected with
K. pneumoniae C2 and treated with antimicrobial agents were always lower than in the control group
(cefepime, 4.4 ± 0.5; imipenem, 4.6 ± 0.4; meropenem, 4.7 ± 0.5; control group, 5.6 ± 0.8; p < 0.01). No
signiﬁcant differences were observed among the groups receiving therapy (p > 0.05). Bacterial lung
clearance was higher in treated animals than in control animals following infection with K. pneumoniae
C2(pMG252) (cefepime, 4.5 ± 0.4; imipenem, 4.0 ± 0.3; meropenem, 4.6 ± 0.4; control group, 6.1 ± 0.6;
p < 0.01), with imipenem producing better clearance than either cefepime or meropenem (p < 0.05).
Thus, in the guinea-pig pneumonia model, cefepime, imipenem and meropenem were each effective
against the porin-deﬁcient K. pneumoniae strain C2 and its derivative expressing the plasmid-mediated
AmpC type b-lactamase FOX-5.
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INTRODUCTION
Infections caused by Klebsiella pneumoniae isolates
that produce plasmid-mediated enzymes related
to the AmpC-type chromosomal b-lactamases of
Gram-negative bacteria (PACBLs) are becoming a
serious therapeutic problem [1]. Most organisms
producing PACBLs behave like derepressed
mutants of organisms encoding AmpC-type
chromosomal b-lactamases, and are commonly
resistant to penicillins, ﬁrst- and second-genera-
tion cephalosporins, cephamycins, oxyimino-ce-
phalosporins, and combinations of b-lactams and
classical b-lactamase inhibitors [1]. Zwitterionic
cephalosporins and carbapenems, which penet-
rate very efﬁciently through the outer-membrane
of Gram-negative bacteria [2] and are poor sub-
strates for PACBLs, are frequently active in vitro
against organisms producing high levels of
AmpC-type b-lactamases [1,3,4]. PACBLs have
been found worldwide in K. pneumoniae, Klebsiella
oxytoca, Escherichia coli, Salmonella spp., Proteus
mirabilis and other enterobacteria [1,5,6], and the
results of recent epidemiological studies with
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clinical isolates indicate that microorganisms with
this resistance mechanism are being isolated with
increasing frequency [5,6].
Treatment of infections caused by K. pneumoniae
strains producing PACBLs may be difﬁcult
because of the presence of additional mechanisms
of resistance; for example, the organism may also
express an extended-spectrum b-lactamase,
which precludes the use of zwitterionic cephalo-
sporins [5]. Loss of porins may cause decreased
susceptibility or resistance of PACBL-producing
K. pneumoniae to both zwitterionic cephalosporins
and carbapenems [4]. Plasmids coding for exten-
ded-spectrum b-lactamases or PACBLs can also
encode resistance to aminoglycosides, co-trim-
oxazole, tetracycline or ﬂuoroquinolones, or resist-
ance determinants could be present on additional
plasmids [1,7]. Other chromosomal mutations may
also be present in genes causing topoisomerase
changes or involved in active efﬂux [8].
It has been shown previously [4] that, with a
standard inoculum of 105 CFU ⁄mL, the porin-
deﬁcient strain K. pneumoniae C2 containing
plasmid pMG252 (which codes for the PACBL
FOX-5) [1 9] is resistant to ampicillin, cephalothin,
cefoxitin, ceftazidime and cefotaxime, either
alone or combined with clavulanic acid, but is
susceptible to cefepime, imipenem and merope-
nem. The organism became resistant to cefepi-
me, and less susceptible to imipenem and
meropenem, when an inoculum of 107 CFU ⁄mL
was used. In order to evaluate the in-vivo
signiﬁcance of these ﬁndings, the present study
tested cefepime, imipenem and meropenem in
an experimental guinea-pig pneumonia model,




K. pneumoniae C2 is a ceftazidime-susceptible strain derived
in vitro from the clinical isolate K. pneumoniae NEDH-1
(deﬁcient in porins OmpK35 and OmpK36, and producing
SHV-2) [4]. Plasmid pMG252 was obtained from a clinical
isolate of K. pneumoniae [10] and codes for blaFOX-5, the
quinolone-resistance determinant qnr, and additional genes
involved in resistance to chloramphenicol, kanamycin, gen-
tamicin, streptomycin, sulphamethoxazole, tobramycin, trim-
ethoprim and mercuric chloride [9]. Plasmid pMG252 was
introduced into K. pneumoniae C2 by conjugation [11], and was
found to be stable following at least ten subcultures in
antibiotic-free medium (data not shown).
Antibiotics
Imipenem plus cilastatin was obtained from Merck, Sharp and
Dohme (Madrid, Spain), meropenem from AstraZeneca
(Madrid, Spain) and cefepime from Bristol-Myers Squibb
(Madrid, Spain).
Susceptibility tests and time-kill curve experiments
MICs of cefepime, imipenem and meropenem against
K. pneumoniae strains C2 and C2(pMG252) were determined
by macrodilution according to NCCLS guidelines [12], but
with three different inocula (105, 106 and 107 CFU ⁄mL). MICs
were also determined by Etests (AB Biodisk, Solna, Sweden),
used according to the manufacturer’s instructions.
Minimum bactericidal concentrations (MBC2 s) were deter-
mined by subculturing 100-lL aliquots from inoculated tubes
containing antimicrobial concentrations higher than or equal to
the MIC of each agent on to antibiotic-free Mueller–Hinton
agar. Plates were incubated at 35C for 48 h, and colonies were
counted. The MBC was deﬁned as the concentration that killed
‡ 99.9% of the initial inoculum.
The bactericidal activities of cefepime, imipenem and
meropenem against the two tested strains were determined
by the kill-curve method, in which their killing activities were
determined over time (0 h, 3 h, 6 h and 24 h) with a starting
inoculum of c. 5–6 · 105 CFU ⁄mL and concentrations of the
antimicrobial agents equivalent to 1· MIC and 4· MIC.
Determination of b-lactamase activity
b-Lactamase activity was determined spectrophotometrically
as described previously [13], with crude supernatants of
sonicated cells as a source of enzyme, and cephaloridine
(0.1 mM; Sigma, Madrid, Spain) as the substrate. One unit of
enzyme was deﬁned as the amount of enzyme that hydrolysed
1 lmol ⁄min of substrate at 30C, as determined at 295 nm.
Animals
Hartley strain guinea-pigs (weight, 350–400 g) were obtained
from B & K Universal (Barcelona, Spain). The animals had a
speciﬁc pathogen-free sanitary status. Animals were housed
in regulation cages and were given free access to food and
water.
Drug pharmacokinetics
The levels of cefepime, imipenem and meropenem were
determined in plasma after the administration of single
intramuscular doses (60 mg ⁄ kg) of each antimicrobial agent.
Blood was extracted by cardiac puncture after 10, 15, 30, 60,
90, 120 and 150 min from anaesthetised non-infected guinea-
pigs, in groups of three at each time-point. The drug
concentrations in plasma were measured with a bioassay
method, with Micrococcus luteus ATCC 9341 as the indicator
strain. The maximum plasma concentration (Cmax in mg ⁄L)
and the terminal half-life (t1 ⁄ 2 in h) were calculated with
the PKCALC program [14]. The time during which the
plasma concentration remained above the MIC (DT ⁄MIC, h)
was estimated by extrapolation from the regression line for
plasma elimination [15], with use of the MIC obtained with
an inoculum of 105 CFU ⁄mL.
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Experimental pneumonia model in guinea-pigs
Pennington’s model [16–19] was used for the production of
pneumonia. The guinea-pigs were anaesthetised by intraperi-
toneal injection of ketamine hydrochloride (Parke-Davis, Bar-
celona, Spain) 100 mg ⁄ kg, plus, locally, with 0.2 mL of
lidocaine 2% w ⁄v (Braun Medical, Jae´n, Spain). A midline
aseptic incision was made in the neck, the trachea was
exposed, and a 25 G needle was inserted between the tracheal
rings. Then, 0.25 mL of an inoculum containing c. 109 CFU ⁄mL
was instilled into the trachea. The needle was removed
inmediately after inoculation, the neck was sutured, and the
animals were placed upright for 10–15 min to facilitate distal
migration of the bacteria by gravity.
K. pneumoniae strains C2 and C2(pMG252) were used to
induce pneumonia in guinea-pigs. The inoculum was pre-
pared from an 18–20-h culture of K. pneumoniae in trypticase-
soy broth (TSB; Becton-Dickinson Microbiology Systems,
Cockeysville, MD, USA) at 37C. To obtain the ﬁnal inoculum,
the bacterial suspension was mixed with the same volume of
porcine mucin (M-2378; Sigma, St Louis, MO, USA) diluted to
10% v ⁄v in saline. The size of the inoculum was measured for
each experiment. Histological studies were performed on
lungs from animals infected with K. pneumoniae C2 or
C2(pMG252) and not treated with antimicrobial agents (see
below), in order to evaluate inﬂammatory changes.
Antimicrobial treatment
To evaluate the effectiveness of the different treatment regi-
mens, 49 guinea-pigs were inoculated with the C2 strain and
46 guinea-pigs with C2(pMG252), and then divided into four
groups. The control groups received sterile saline intramus-
cularly for 72 h (n = 17 and n = 11 for C2 and C2(pMG252),
respectively), while the other three groups received one of the
following treatments for 72 h: (1) imipenem 240 mg ⁄ kg ⁄day
intramuscularly (n = 10 and n = 12 for C2 and C2(pMG252),
respectively); (2) meropenem 240 mg ⁄ kg ⁄day intramuscularly
(n = 12 and n = 12 for C2 and C2(pMG252), respectively); or
(3) cefepime 240 mg ⁄ kg ⁄day intramuscularly (n = 10 and
n = 11 for C2 and C2(pMG252), respectively). The ﬁrst dose
of every antibiotic was administered 4 h after inoculation, with
the following dosing schedule: 60 mg ⁄kg at 08:00 and 14:00 h,
and 120 mg ⁄ kg at 20:00 h. In order to conﬁrm that the drugs
were not directly toxic to the animals, each antibiotic was
given to groups of ten non-infected guinea-pigs for 72 h.
All the animalswere observed during treatment for 72 h. The
surviving guinea-pigs were killed humanely 4 h after the last
dose by intraperitoneal administration of sodium thiopental 5%
w ⁄v (Braun Medical, Barcelona, Spain). Following death, tho-
racotomy was performed; the heart and lungs were extracted
together, and the lungs were later separated on a sterile Petri
dish andweighed. The lungswere homogenised (Stomacher 80;
Tekmar, Cincinnati, OH, USA) in 10 mL of sterile saline
solution, after which viable counts were determined by plating
100-lL aliquots of ten-fold dilutions on Columbia sheep blood
agar plates and incubating for 24 h at 37C. The results were
expressed as mean ± SD of the log10 CFU ⁄g of lung.
Selection and characterisation of antibiotic-resistant mutants
Selection of mutants derived from either K. pneumoniae C2 or
C2(pMG252) was performed by inoculation of lung homogen-
ates either on media containing 4·MIC of cefepime, imipenem
or meropenem against the tested strain, or on media contain-
ing a gradient (0–16· MIC) of each antibiotic. The latter
approach was used in an attempt to obtain mutants with
different levels of resistance to the selecting agent. Lungs from
three animals treated with cefepime, imipenem or meropenem
were used in these assays. Colonies were counted after
incubation at 35C for 48 h.
In a parallel experiment, mutants were also selected under
the same conditions with use of a suspension of bacteria grown
in TSB (35C for 20 h). The frequency of mutation was
expressed as the ratio between the number of colonies on
plates containing 4· MIC of each agent and the size of the
original inoculum. The results from gradient plates were
evaluated qualitatively by counting the number of colonies
growing on zones of the plates corresponding to 0·, 4·, 8· and
16· MIC.
Up to four different isolated colonies on every single- or
gradient-concentration plate were selected for further studies.
Bacteria were subcultured twice on antibiotic-free Mueller–
Hinton agar. The MIC of the agent used for selection was
determined for every original colony by microdilution, as
described above. True mutants were deﬁned as those for
which the MIC of the selecting agent increased at least four-
fold. b-Lactamase activity in mutants and the corresponding
parent strains were determined as described above.
Statistical analysis
Numbers of surviving animals, numbers of sterile lung tissue
specimens, and b-lactamase activity in parental strains and
derived mutants were evaluated with Fisher’s exact test. A
p value < 0.05 was considered signiﬁcant. CFU ⁄ g of lung tissue
were analysed with ANOVA and post-hoc tests (Tukey–Kramer
and Dunnet tests). The SPSS 8.0 statistical package (SPSS Inc.,
Chicago, IL, USA) was used.
RESULTS
In-vitro tests
MICs of cefepime, imipenem and meropenem
against K. pneumoniae C2 and C2(pMG252) are
shown in Table 1. MIC results obtained with the
macrodilution method with an inoculum of
105 CFU ⁄mL were within one dilution step of
those obtained by Etest and those obtained previ-
ously by microdilution. The results of time-kill
curve experiments with cefepime are presented in
Fig. 1. Cefepime at 1· or 4· MIC produced a
> 2 log10 reduction in the number of viable bacteria
in comparison with the untreated control for both
K. pneumoniae C2 and C2(pMG252) at 3 h or 6 h.
This killing activity wasmaintained at 24 h against
the parental strain C2. In the transconjugant
expressing FOX-5, bacterial regrowth was
observed at 24 h (particularly at 1·MIC), although
the reduction in the number of viable bacteria
remained at > 2 log10 at that time. Imipenem and
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meropenemwere both bactericidal against the two
tested strains after 3 h or 6 h (> 2 log10 reduction in
viable bacteria compared to the control). No bac-
terial regrowth ofK. pneumoniaeC2 or C2(pMG252)
was observed at 24 h with either imipenem or
meropenem (data not shown).
Pharmacokinetic and histological studies
The pharmacokinetic ⁄pharmacodynamic param-
eters (Cmax, t1 ⁄ 2, and DT ⁄MIC) for each antimi-
crobial agent are shown in Table 2.
Lungs from untreated animals showed acute
pneumonia, predominantly central, and atelecta-
sis. The lungs appeared haemorrhagic and had
gross inﬂammatory lesions. Microscopic exam-
ination revealed perivascular inﬂammatory cells
(data not shown).
Therapeutic efﬁcacy in experimental pneumonia
Survival
The low mortality rates in control groups preclu-
ded the use of mortality rate as an indicator of
therapeutic efﬁcacy (Tables 3 and 4).
Bacterial clearance from lung
There were no sterile lungs in either the control
group or the treatment groups. The bacterial

















































Fig. 1. Viable bacterial counts in time-kill curve assays
with cefepime against (a) Klebsiella pneumoniae C2, and (b)
K. pneumoniae C2 (pMG252) at 1· MIC or 4· MIC, in
comparison with a cefepime-free culture (control).
Table 1. MICs and MBCs (mg ⁄L) of cefepime, imipenem
and meropenem against two strains of Klebsiella pneumoniae











105 106 107 105 106 107 105 106 107
C2 MIC 0.5 1 1 0.5 0.5 2 0.25 0.5 1
MBC 0.5 1 1 0.5 1 2 0.25 1 2
C2 (pMG252) MIC 4 32 > 64 0.5 1 2 0.5 2 4
MBC 32 > 64 > 64 0.5 1 4 0.5 2 4
Table 2. Cmax and t1 ⁄ 2 after a single dose (60 mg ⁄ kg) of
cefepime, imipenem or meropenem in guinea-pigs, and














Cefepime 176.5 0.64 2.46 2.41
Imipenem 21.6 0.66 2.32 2.32
Meropenem 43.9 0.47 2.26 2.25
Table 3. Effect of antibiotic therapy on the mortality and
the clearance of Klebsiella pneumoniae C2 from the lungs in
guinea-pigs
Treatment Dosage n Mortality (%) Log10 CFU ⁄ g of lung
Control Saline 17 0 5.65 ± 0.82
Cefepime 240 mg ⁄ kg ⁄day 10 0 4.41 ± 0.50a
Imipenem 240 mg ⁄ kg ⁄day 10 20 4.65 ± 0.39a
Meropenem 240 mg ⁄ kg ⁄day 12 8.3 4.72 ± 0.55a
n, number of animals tested.
ap < 0.01 compared to the control group.
Table 4. Effect of antibiotic therapy on mortality and the
clearance of Klebsiella pneumoniae C2(pMG252) from the
lungs in guinea-pigs
Treatment Dosage n Mortality (%) Log10 CFU ⁄ g of lung
Control Saline 11 18 6.13 ± 0.58
Cefepime 240 mg ⁄ kg ⁄day 11 0 4.54 ± 0.45a
Imipenem 240 mg ⁄ kg ⁄day 12 0 4.04 ± 0.33a,b
Meropenem 240 mg ⁄ kg ⁄day 12 0 4.68 ± 0.36a
n, number of animals tested.
ap < 0.01 compared to the control group; bp < 0.05 compared to cefepime or
meropenem.
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are shown in Tables 3 and 4. When animals
infected with the parental strain C2 were consid-
ered, all the groups receiving treatment showed
greater lung clearance of K. pneumoniae than did
the control group (p < 0.01), but no signiﬁcant
differences were observed between the three
antimicrobial agents. When guinea-pigs were
infected with the transconjugant producing
FOX-5, signiﬁcantly higher lung clearance of
K. pneumoniae was seen in animals treated with
cefepime, imipenem or meropenem than in the
control group (p < 0.01), and imipenem produced
a greater reduction (p < 0.05) in the number of
viable bacteria in the lungs than did either
cefepime or meropenem.
Selection of resistant mutants
When the lung homogenates from three guinea-
pigs infected with K. pneumoniae C2 and treated
with cefepime were used to select resistant
mutants, bacteria were recovered from plates
containing 4· MIC of cefepime (at a frequency
of c. 10)3) and from gradient plates in the zone up
to 4· MIC from two of the animals. MICs of
cefepime against these mutants were in the range
4–16 mg ⁄L (compared to an MIC of 0.5 mg ⁄L for
the parent strain). The b-lactamase activities
(mU ⁄mg of protein in crude sonicate) of the
mutants evaluated were 313, 303, 233 and
219 mU ⁄mg, compared to 5 mU ⁄mg for K. pneu-
moniae C2 (p < 0.01). No resistant mutants
derived from K. pneumoniae C2 were obtained
from lung homogenates of animals treated with
imipenem or meropenem. Similarly, no resistant
mutants were obtained from any of the lung
homogenates of the three animals treated with
cefepime, imipenem or meropenem and infected
with K. pneumoniae C2 (pMG252), either on plates
containing 4· MIC of antibiotic or on gradient
plates.
When TSB-grown bacteria were used for selec-
tion of resistant mutants, > 103 colonies grew from
K. pneumoniae C2(pMG252) on plates containing
4· MIC of cefepime. Four independent colonies
were selected from individual plates with bacter-
ial growth, but in each case the MICs of the
selecting agents were within one dilution step of
the MIC for the corresponding parent strain. This
indicated that none of the chosen colonies
contained true (as deﬁned for the purposes of
this investigation) antibiotic-resistant mutants.
However, no bacterial growth was obtained from
the parent C2 strain, and no growth was obtained
with either K. pneumoniae C2 or C2 (pMG252)
when bacteria grown in vitro were used in an
attempt to select imipenem- or meropenem-resist-
ant mutants on plates containing 4· MIC of the
corresponding agent. Similarly, no colonies were
recovered from the gradient plates of any of the
three b-lactams beyond the zone corresponding to
4· MIC of the corresponding agent; however,
isolated colonies were observed from the MIC
limit up to 4· MIC of cefepime.
DISCUSSION
PACBLs have been found in a variety of entero-
bacteria, but they seem to be particularly frequent
among K. pneumoniae isolates from the hospital
setting [1,5,6]. The spectrum of resistance
observed among K. pneumoniae isolates expressing
plasmid-mediated PACBLs is often similar to that
of bacteria producing derepressed chromosomal
AmpC enzymes; i.e., in-vitro susceptibility to
zwitterionic cephalosporins and carbapenems
unless other resistance mechanisms are present.
Loss of both OmpK35 and OmpK36 porins, in
combination with the presence of PACBLs, has
resulted in decreased susceptibility to cefepime
and resistance to both imipenem and meropenem
[4]. In other cases, resistance to cefepime in
K. pneumoniae producing PACBLs is the conse-
quence of production by the same organisms of
an extended-spectrum b-lactamase [7].
A previous study [4] showed that PACBL
production in porin-deﬁcient K. pneumoniaemight
cause in-vitro resistance to carbapenems. Cefep-
ime (and in some cases cefpirome) was still active,
unless a high inoculum was used. FOX-5 was
unable to confer in-vitro resistance to carbapen-
ems, but it increased the MIC of cefepime from
0.25 to 4 mg ⁄L with an inoculum of 105 CFU ⁄mL,
and to > 64 mg ⁄L with an inoculum of
107 CFU ⁄mL. This was conﬁrmed in the present
study, where resistance to cefepime was also
found with an inoculum of 106 CFU ⁄mL.
A guinea-pig pneumonia model was chosen for
the present study. This experimental model was
described initially for the evaluation of different
antimicrobial treatments and for investigating the
pathogenesis of pneumonia caused by Pseudo-
monas aeruginosa [16–19]. The main advantages of
this model are the easy handling of the animals in
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the laboratory, the similarity between the immune
systems of guinea-pigs and humans, and the
absence of endemic colonisation of the respiratory
tract, which is frequent with other laboratory
animals such as rats [20]. Additionally, the gui-
nea-pig model of experimental pneumonia allows
meropenem to be evaluated, since, in contrast to
what happens in the mouse experimental model,
meropenem is not degraded by the renal dehy-
dropeptidase I in guinea-pigs [21]. The patholo-
gical ﬁndings in the model conﬁrmed that the
animals developed pneumonia and that, inde-
pendent of FOX-5 expression, bacterial counts in
control animals (0.45–1.35 · 106 CFU ⁄ g lung)
were signiﬁcantly higher than those in treated
animals. The main limitations of the model are the
absence of mortality and the difﬁculty in estab-
lishing a high bacterial inoculum when Gram-
negative microorganisms other than P. aeruginosa
are used in immunocompetent guinea-pigs.
The in-vivo activities of cefepime and carbap-
enems have also been evaluated in a non-lethal
model of pneumonia caused by Enterobacter
cloacae in immunocompetent rats [22,23]. It was
proved that both cefepime and imipenem were
effective against strains either producing a basal
level of AmpC or hyperproducing AmpC, while
ceftazidime was not active against the hyperpro-
ducing AmpC strain [22]. In another study by
the same group [23], strains producing a basal
level of both AmpC and the NmcA carbapene-
mase, and a derivative that overproduced both
enzymes, were evaluated. It was observed that
carbapenems were not useful, that ceftazidime
only caused a signiﬁcant decrease in bacterial
counts in the lungs for strains producing basal
levels of enzymes, and that only cefepime was
effective against strains with both basal levels
and overproduction of AmpC and NmcA
b-lactamases.
The in-vitro data obtained on the activities of
cefepime, imipenem and meropenem conﬁrm and
expand previous observations [4]. MIC values
indicated good bacteriostatic and bactericidal
activity for both imipenem and meropenem
against K. pneumoniae C2, and this effect was not
dependent on FOX-5 expression. In contrast,
cefepime had high bacteriostatic and bactericidal
activity against strain C2, but reduced activity
(particularly with a high inoculum) against the
transconjugant producing FOX-5. Time-kill stud-
ies supported those ﬁndings, in that bacterial
regrowth of the FOX-5-producing strain was
observed with cefepime at 24 h, but not with the
two carbapenems. The clinical signiﬁcance of the
bacterial regrowth observed is unclear, but this
observation reinforces the importance of an ade-
quate cefepime administration schedule for the
maintenance of concentrations above the MIC
between dosage intervals [24].
An additional risk of therapy failure would
result from the emergence of resistant mutants
[25,26]. Two different approaches were used for
mutant selection and, in general, similar results
were obtained with both methods. Neither imi-
penem nor meropenem selected mutants from
K. pneumoniae C2 or its FOX-5-producing deriv-
ative, with bacteria grown either in vitro or in vivo.
Although in-vitro growth of K. pneumoniae
C2(pMG252) was noted on plates containing 4·
MIC of cefepime, these organisms did not seem to
be actual mutants, and perhaps represented
organisms able to survive the bactericidal activity
of cefepime by unknown mechanisms related to
the phenomenon of tolerance [27]. Additional
studies with an in-vivo model in which a high
lung inoculum is achieved would be needed to
evaluate the clinical signiﬁcance of these organ-
isms. The only true stable mutants were selected
by cefepime from K. pneumoniae C2 grown in vivo.
MICs for these mutants increased 16–32-fold, and
approached the recognised breakpoint for clinical
resistance to cefepime. These mutants have not
yet been characterised fully, but preliminary
results indicate that they are b-lactamase over-
producers. Strain C2 was derived originally from
a clinical isolate producing two b-lactamases of pI
5.4 (compatible with TEM-1) and pI 7.6 (SHV-2).
K. pneumoniae C2 has lost SHV-2, but still expres-
ses the pI 5.4 enzyme [4]. The fact that similar
mutants were not obtained from C2(pMG252) on
plates containing 4· MIC could be explained by
the much higher absolute concentration of cefep-
ime (16 mg ⁄L) involved.
All three b-lactams tested were shown to have
in-vivo activity against K. pneumoniae C2, whether
or not FOX-5 was produced, as inferred from the
signiﬁcantly lower bacterial counts in treated
animals than in control animals. Doses of
240 mg ⁄kg ⁄day were chosen because they
achieved similar DT ⁄MIC of the three antimicro-
bial agents with both strains (37.5% and 41% of
the dosing interval; Table 2) and pharmacody-
namic parameters correlating with the antimicro-
36 Clinical Microbiology and Infection, Volume 11 Number 1, January 2005
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 31–38
bial activity of b-lactams in animal models [28].
Cefepime, imipenem and meropenem reduced
the bacterial counts in lung tissues of animals
infected by K. pneumoniae C2 by c. 1 log10. The
reduction was even higher (c. 1.5–2 log10) for the
strain producing FOX-5; in this case, the greatest
reduction was noted with imipenem. This agent
was also superior to cefepime in reducing the
mortality rate caused by SHV-5-producing
K. pneumoniae in a septic model in mice [29], in
which the MICs of cefepime were 1 and
> 256 mg ⁄L with inocula of 105 and 107 CFU ⁄mL,
compared with 0.125 and 0.5 mg ⁄L for imipenem
[29]. It is clear that FOX-5 expression is critical in
decreasing the in-vitro activity of cefepime, but
the reduction in the number of viable bacteria in
lungs suggests that expression of this b-lactamase
does not imply that cefepime would not be
clinically useful, provided that pharmacodynamic
parameters are maintained adequately.
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